Immunocytochemical Characterization of Alzheimer Disease Hallmarks in APP/PS1 Transgenic Mice Treated with a New Anti-Amyloid-β Vaccine

Figure 4

Clearing effect of established AD hallmarks by EB101 vaccine in the brains of PS1/APP transgenic mice. Transverse brain sections of 21-month-old mice of the treatment period (phase II), showing almost complete reduction of AD hallmarks after EB101 vaccine immunization compared with EB102-immunized mice and PBS control groups.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)